Compare GIS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | JAZZ |
|---|---|---|
| Founded | 1866 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 15.0B |
| IPO Year | 2003 | 2007 |
| Metric | GIS | JAZZ |
|---|---|---|
| Price | $33.89 | $236.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | $42.07 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 9.5M | 816.4K |
| Earning Date | 03-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 3.56 | ★ 4.43 |
| Revenue | ★ $2,037,800,000.00 | $1,618,693,000.00 |
| Revenue This Year | N/A | $6.22 |
| Revenue Next Year | N/A | $7.68 |
| P/E Ratio | ★ $9.50 | $51.84 |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $31.75 | $105.00 |
| 52 Week High | $55.13 | $243.32 |
| Indicator | GIS | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 58.56 |
| Support Level | $32.20 | $224.23 |
| Resistance Level | $34.49 | $243.32 |
| Average True Range (ATR) | 0.86 | 6.98 |
| MACD | 0.17 | -1.65 |
| Stochastic Oscillator | 80.27 | 60.69 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.